Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy

Arthritis Research and Therapy

Volumn 12, Issue 5, 2010, Pages

  Quan, Ling dong ^a   Purdue, P Edward ^b   Liu, Xin Ming ^a   Boska, Michael D ^c   Lele, Subodh M ^c   Thiele, Geoffrey M ^c,d   Mikuls, Ted R ^c,d   Dou, Huanyu ^a,e   Goldring, Steven R ^b   Wang, Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^e Paul L Foster School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; COPOLYMER; CYTOKINE; DEXAMETHASONE DERIVATIVE; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; P DEX; PRODRUG; SODIUM CHLORIDE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; DEXAMETHASONE; FREUND ADJUVANT; HYDROXYPROPYL METHACRYLATE; IMMUNOLOGICAL ADJUVANT; METHACRYLIC ACID DERIVATIVE;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTHRITIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL CULTURE; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOHISTOCHEMISTRY; INFLAMMATORY DISEASE; MACROPHAGE; MONOCYTE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PUBLICATION; RAT; RHEUMATOID ARTHRITIS; STAINING; SYNOVIOCYTE; TISSUE INJURY; ANIMAL; BONE MARROW CELL; CAPILLARY PERMEABILITY; CELL SEPARATION; CHEMICALLY INDUCED DISORDER; CONFOCAL MICROSCOPY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; SYNOVIUM; TISSUE DISTRIBUTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CAPILLARY PERMEABILITY; CELL SEPARATION; DEXAMETHASONE; FIBROBLASTS; FLOW CYTOMETRY; FREUND'S ADJUVANT; HUMANS; IMMUNOHISTOCHEMISTRY; METHACRYLATES; MICROSCOPY, CONFOCAL; MYELOID CELLS; PRODRUGS; RATS; SYNOVIAL MEMBRANE; TISSUE DISTRIBUTION;

EID: 77956473895     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3130     Document Type: Article

References (21)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009, 373:659-672. 10.1016/S0140-6736(09)60008-8, 19157532.
2. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009, 5:531-541. 10.1038/nrrheum.2009.182, 19798027.
3. Vanniasinghe AS, Bender V, Manolios N. The potential of liposomal drug delivery for the treatment of inflammatory arthritis. Semin Arthritis Rheum 2009, 39:182-196. 10.1016/j.semarthrit.2008.08.004, 18926560.
4. Tarner IH, Müller-Ladner U. Drug delivery systems for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv 2008, 5:1027-1037. 10.1517/17425247.5.9.1027, 18754751.
5. Liu XM, Miller SC, Wang D. Beyond oncology - application of HPMA copolymers in non-cancerous diseases. Adv Drug Deliv Rev 2010, 62:258-271. 10.1016/j.addr.2009.10.006, 19909776.
6. Richards PJ, Williams AS, Goodfellow RM, Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 1999, 38:818-825. 10.1093/rheumatology/38.9.818, 10515641.
7. Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, de Waal Malefijt MC, van de Putte LB, Storm G, van den Berg WB. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 2000, 43:1951-1959. 10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K, 11014344.
8. Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y, Naparstek Y. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum 2008, 58:119-129. 10.1002/art.23230, 18163482.
9. Wunder A, Müller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003, 170:4793-4801.
10. Kopeček J, Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010, 62:122-149. 10.1016/j.addr.2009.10.004, 19919846.
11. Wang D, Miller SC, Sima M, Parker D, Buswell H, Goodrich KC, Kopečková P, Kopeček J. The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study. Pharm Res 2004, 21:1741-1749. 10.1023/B:PHAM.0000045232.18134.e9, 15553217.
12. Wang D, Miller SC, Liu XM, Anderson B, Wang XS, Goldring SR. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther 2007, 9:R2. 10.1186/ar2106, 1860059, 17233911.
13. Liu XM, Quan LD, Tian J, Alnouti Y, Fu K, Thiele GM, Wang D. Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis. Pharm Res 2008, 25:2910-2919. 10.1007/s11095-008-9683-3, 2593120, 18649124.
14. Look DC, Locker DR. Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum 1970, 41:250-251.
15. Ewing JR, Brown SL, Lu M, Panda S, Ding G, Knight RA, Cao Y, Jiang Q, Nagaraja TN, Churchman JL, Fenstermacher JD. Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab 2006, 26:310-320. 10.1038/sj.jcbfm.9600189, 16079791.
16. Duncan R, Cable HC, Rejmanová P, Kopeček J, Lloyd JB. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim Biophys Acta 1984, 799:1-8.
17. Rakshit DS, Ly K, Sengupta TK, Nestor BJ, Sculco TP, Ivashkiv LB, Purdue PE. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis. J Bone Joint Surg Am 2006, 88:788-799. 10.2106/JBJS.E.00711, 16595469.
18. Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, Weissleder R, Mathis D, Benoist C. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol 2006, 7:284-292. 10.1038/ni1306, 16444258.
19. Zarabi B, Nan A, Zhuo J, Gullapalli R, Ghandehari H. Macrophage targeted N-(2-hydroxypropyl)methacrylamide conjugates for magnetic resonance imaging. Mol Pharm 2006, 3:550-557. 10.1021/mp060072i, 17009854.
20. Wang D, Pechar M, Li W, Kopečková P, Brömme D, Kopeček J. Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. Biochemistry 2002, 41:8849-8859. 10.1021/bi0257080, 12102627.
21. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.